BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/440/0.1/21.06.24 | Delayed Deutsche Boerse AG 05:14:54 18/06/2024 pm IST | ||
| 3.09 EUR | -12.46% |
|
| Current month | +113.94% | ||
| 1 month | +169.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 18/24/18 | 3.09 | -12.46% |
| 17/24/17 | 3.53 | -13.90% |
| 14/24/14 | 4.1 | +6.22% |
| 13/24/13 | 3.86 | +6.34% |
| 12/24/12 | 3.63 | -9.70% |
Delayed Quote Deutsche Boerse AG
Last update June 18, 2024 at 05:14 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM345K |
| ISIN | DE000VM345K8 |
| Date issued | 17/10/2023 |
| Strike | 440 $ |
| Maturity | 21/06/2024 (3 Days) |
| Parity | 10 : 1 |
| Emission price | 1.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.5 € |
|---|---|
| Lowest since issue | 0.34 € |
| Spread | 0.11 € |
| Spread % | 3.42% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Warrants
- Warrant
